Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

By N. Ahmed, V. Brawley, M. Hegde, C. Robertson, A. Ghazi, C. Gerken, E. Liu, O. Dakhova, A. Ashoori, A. Corder and 16 more. Journal of Clinical Oncology, 2015

907 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/c7a885c47633cba688407d1c4934db549696b8b6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, neutral): “These toxicities include cytokine-release syndrome (CRS), haemophagocytic lymphohistiocytosis (HLH) and/or macrophage activation syndrome (MAS), and a distinct neurotoxicity now referred to as immune effector cell-associated neurotoxicity syndrome (ICANS) 60 .”
The Principles of Engineering Immune Cells to Treat Cancer (2017, result): “In contrast, a trial using a lower-affinity CAR targeting HER2 using a second-generation signaling domain and lower doses of T cells was safely completed with evidence of clinically beneficial antitumor effects (Ahmed et al., 2015).”
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma (2017, background): “8/F GBM Yes, x3 Yes (1) TMZ + Hydrox (2) TMZ (3) CCNU + Bev (4) TMZ + Hydrox + Bev (5) Irino + Bev (1) TMZ + Iniparib (2) Carbo + Iniparib 27.”
Tumor Antigen Escape from CAR T-cell Therapy. (2018, background): “Moreover, Ahmed and colleagues have since used escalating doses of HER2-CD28-ζ CAR T cells to treat patients with sarcomas and demonstrated both safety and initial signs of clinical efficacy, including a CR in a patient with rhabdomyosarcoma in his bone marrow (82, 83).”